Related Experiment Videos
Implantable cardioverter-defibrillator therapy for prevention of sudden cardiac death
M Akhtar1, M R Jazayeri, J S Sra
1University of Wisconsin Medical School, Milwaukee.
Insights
Sudden cardiac death is a risk for patients with symptomatic ventricular tachycardia (VT) or ventricular fibrillation (VF). Implantable cardioverter-defibrillators (ICDs) offer superior survival rates compared to antiarrhythmic drugs for these high-risk patients.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Background:
- Symptomatic ventricular tachycardia (VT) and ventricular fibrillation (VF) pose a significant risk of sudden cardiac death (SCD).
- Current therapeutic options aim to reduce SCD incidence in high-risk individuals.
Purpose of the Study:
- To evaluate the efficacy of various therapeutic choices for reducing SCD in patients with symptomatic VT/VF.
- To compare the survival rates and risks associated with different treatment modalities, including antiarrhythmic agents, VT ablation, and implantable cardioverter-defibrillator (ICD) therapy.
Main Methods:
- Review of existing therapeutic strategies for managing symptomatic VT/VF.
- Comparison of survival data and operative mortality rates for ICD therapy versus antiarrhythmic agents and surgical interventions.
Main Results:
- ICD therapy demonstrates an overall SCD incidence of less than 2% per year in recipients, a survival rate superior to antiarrhythmic agents.
- VT surgical therapy can achieve comparable survival but carries a higher minimal operative mortality than ICD therapy.
- ICD therapy emerges as a potentially sole realistic option for patients with noninducible VT/VF, inducible polymorphic VT, or those refractory/intolerant to antiarrhythmic agents with poor left ventricular function.
Conclusions:
- ICD therapy offers a significant survival advantage for patients at high risk of SCD due to symptomatic VT/VF.
- For specific patient subgroups, particularly those with limited treatment options or poor ventricular function, ICDs represent the most viable therapeutic strategy.
Abstract:
Patients with known symptomatic VT or VF are at high risk for sudden cardiac death. Various therapeutic choices can be used to reduce the incidence of arrhythmic sudden cardiac death. These include beta-blockers, class I and III antiarrhythmic agents, VT focal ablations, and ICD therapy. The overall incidence of sudden cardiac death in ICD recipients is less than 2% per year, a rate of survival not achieved with any of the available antiarrhythmic agents. VT surgical therapy can produce comparable survival results, but the minimal operative mortality is higher than that with ICD therapy. In patients with noninducible VT/VF or inducible polymorphic VT, and in those refractory to or intolerant of antiarrhythmic agents and poor left ventricular function, ICD therapy may be the only realistic option.